Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +55

Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Wall Street Zen

📉 Wall Street Zen downgraded Biogen to a 'Hold' rating, contrasting with a broader analyst consensus of 'Moderate Buy' and a $223.36 target price.

📈 The company reported Q2 earnings of $3.60 EPS, beating the consensus estimate of $2.94 by $0.66.

💰 Revenue for the quarter reached $2.74 billion, exceeding analyst estimates of $2.46 billion and growing 3.4% year-over-year.

📊 Biogen achieved an 11.18% return on equity and an 8.32% net margin during the reported period.

🔮 The company set FY 2026 EPS guidance between $12.00 and $13.00, slightly below the average analyst expectation of $12.49.

🏦 Institutional investors own 87.93% of the company's outstanding shares as of the latest filing period.

📈 LSV Asset Management increased its holdings by 3.3% in the 4th quarter, now owning approximately $55.7 million worth of stock.

🚀 Contrarius Group Holdings Ltd acquired a new position valued at roughly $11.4 million during the 4th quarter.

💼 Guggenheim upgraded its price objective from $260 to $280 while maintaining a 'Buy' rating on the stock.

📉 Royal Bank of Canada lowered its target price from $242 to $240 but maintained an 'Outperform' rating.

Bullish Signals
  • Biogen reported earnings per share of $3.60, which significantly topped the consensus estimate of $2.94 by $0.66.
  • The company generated revenue of $2.74 billion for the quarter, beating analyst estimates of $2.46 billion.
  • Revenue grew 3.4% compared to the same quarter last year, indicating continued top-line growth.
  • Biogen achieved a return on equity of 11.18% and a net margin of 8.32%, reflecting healthy profitability.
  • Guggenheim increased its price objective from $260.00 to $280.00 while reaffirming a 'Buy' rating.
  • LSV Asset Management grew its holdings by 3.3% in the 4th quarter, adding nearly 10,000 shares.
  • Contrarius Group Holdings Ltd established a new position valued at approximately $11.4 million in the 4th quarter.
Risk Factors
  • Wall Street Zen downgraded Biogen from a 'Buy' to a 'Hold' rating in a recent research note.
  • Royal Bank of Canada cut its price target from $242.00 to $240.00, signaling some caution among analysts.
  • Biogen's FY 2026 guidance of $12.00-$13.00 EPS is below the average analyst expectation of $12.49.
Full Analysis
Biogen (NASDAQ:BIIB) received a rating downgrade to 'Hold' from Wall Street Zen, though the broader analyst consensus remains a 'Moderate Buy' with a target price of $223.36. While some firms like Guggenheim raised their price targets, others such as Royal Bank of Canada lowered theirs, reflecting mixed sentiment among equity research analysts regarding the company's current valuation and strategic outlook. The biotechnology firm reported strong quarterly financial results ending July 29th, posting $3.60 in earnings per share which significantly beat the consensus estimate of $2.94. Revenue reached $2.74 billion, surpassing analyst expectations of $2.46 billion and marking a 3.4% year-over-year increase. The company also reported an 11.18% return on equity and an 8.32% net margin, demonstrating solid profitability despite the mixed analyst ratings. Looking ahead, Biogen has provided full-year 2026 guidance ranging between $12.00 and $13.00 in EPS, which is slightly below the average analyst expectation of $12.49. Institutional ownership remains high at 87.93%, with notable activity from hedge funds like LSV Asset Management and Contrarius Group Holdings Ltd increasing their positions during the recent quarters.